For the Leaders
Article
Big Pharma’s Appetite For AI: Analyzing Recent M&A Deals In Small Molecule Chemistry
AI in drug discovery is reshaping small molecule chemistry through M&A Recursion, Exscientia, Schrödinger and ...
High-Value Partnerships: Notable AI Drug Discovery Out-Licensing Deals In Oncology
Simantini Singh Deo | Jun 24, 2026
Where Is The Money Going? Tracking Biotech AI Seed Funding In Cancer Research
Simantini Singh Deo | Jun 12, 2026
A Founder’s Guide To Computational Chemistry Platforms For Early-Stage Oncology Startups
Simantini Singh Deo | Jun 04, 2026
Other latest content for leaders you may like to read
Big Pharma’s Appetite For AI: Analyzing Recent M&A Deals In Small Molecule Chemistry
AI in drug discovery is reshaping small molecule chemistry through M&A Recursion, Exscientia, Schrödinger and Insilico lead the wave.
by Simantini Singh Deo
High-Value Partnerships: Notable AI Drug Discovery Out-Licensing Deals In Oncology
AI biotechs are out-licensing oncology assets to big pharma at scale. Here's how the deals work, who's leading, and why it's working.
by Simantini Singh Deo
Where Is The Money Going? Tracking Biotech AI Seed Funding In Cancer Research
AI cancer seed funding is surging despite a tighter market. Here's where the money flows, who backs it, and what the bets signal for pharma.
by Simantini Singh Deo
A Founder’s Guide To Computational Chemistry Platforms For Early-Stage Oncology Startups
How oncology startups can use computational chemistry platforms to speed up drug discovery, cut costs, and make smarter research decisions
by Simantini Singh Deo
FDA Computer Software Assurance (CSA): A Definitive Guide for Pharma Leaders
FDA Computer Software Assurance explained, CSA vs CSV, six step framework, SaaS validation and implementation roadmap for pharma leaders.
by Mrudula Kulkarni
